June 8 (Reuters) - Tango Therapeutics said on Monday an experimental drug combination showed strong early results in a small study of patients with advanced pancreatic cancer and that it plans to ...
A combination involving Tango’s experimental therapy appeared to boost response rates in a small clinical trial well beyond ...
Stocktwits on MSN
TNGX stock hits all-time high – Wolfe Research calls Tango Therapeutic’s pancreatic cancer trial data ‘groundbreaking’
Wolfe raised the drug’s global peak sales estimate to about $2.6 billion from $1.9 billion. ・Mizuho analyst Joseph Catanzaro stated that the data ‘starts to tell a potentially very compelling signal ...
The sharp rally pushed the stock toward a record closing high and marked one of its strongest single-day performances in more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results